Ignite Creation Date:
2024-05-06 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06158945
Status:
RECRUITING
Last Update Posted:
2023-12-06
First Post:
2023-11-28
Brief Title:
The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease
Sponsor:
Sohag University
Organization:
Sohag University
Study Overview
Official Title:
The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Sickle cell disease SCD refers to a group of hemoglobinopathies that include mutations in the gene encoding the beta subunit of hemoglobin Within the umbrella of SCD many subgroups exist namely sickle cell anemia SCA hemoglobin SC disease HbSC and hemoglobin sickle-beta-thalassemia beta-thalassemia positive or beta-thalassemia negative Several other minor variants within the group of SCDs also albeit not as common as the varieties mentioned above It is essential to mention the sickle cell trait HbAS which carries a heterozygous mutation and seldom presents clinical signs or symptoms Sickle cell anemia is the most common form of SCD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None